Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Two Years" you should take a better look at your chart. LOL
Funny how things add up for Viaderma...
Statements have been made in the past that "Viaderma is a fraud". "They will never bring a product to market", and they did.
It has been said that "The company will be defeated in court for patent infringement", the case has been "Dismissed (WOP).
It has been said that "The CEO is diluting shares to line his pockets", when one can easily see that the shares have been conservatively distributed as needed to fund the next step to bring "New Products to Market.
It has also been said that "The product doesn't work", although there are other company(s) are attempting to claim rights to the technology.
Funny how the company keeps marching forward despite the false claims.
Soon we will be rewarded for our steadfast support for VDRM.
Oh... I'm sure they maxed out their truckloads with cheap shares by now. Funny how they get quiet from time to time.
The reviews look pretty good too, 11 Five Stars reviews out of 12 is awesome!
VitaStem Sales on Amazon is outstanding, check for yourself.
You can look up the sales rank figures on the Amazon "CamelCamelCamel.com". You will need to register then look up Vitastem. On that page click on "Sales Rank" tab to the right of the "Price History" tab.
Wow, very impressive!
It's worth the DD!
I'm sure Otiko will take advantage of every development and make us aware of the progress going forward.
Despite what many believe, I believe the business is moving along just fine. The business is expanding the product lines and into multiple markets and signing deals along the way. What more can you really expect, with all things considered.
I have a large amount of money in this company, not because I'm stuck in it, but because I believe this risky investment over time has the best chance of making me 5-10 times my money.
The product works, period. Keough thinks so.
Have you even tried the product? I was impressed by the healing rate after I used it on my wounds. Buy a bottle, you're a good investor, you can afford it.
Today Dr. Otiko our CEO is in Mumbai India, (pop.22M.) to participate in the upcoming Beauty & Wellness Executive Service Program, hosted by the United States Department of Commerce. Check-out this travel video of Mumbai (
A train is coming; feel the rail?
I would think the price will be reduced as production increases and if they get insurance to cover the cost, the inflated price will pay-off.
In a recent PR, Otiko mentioned three items; one was the Nigerian deal, done. The second was the Canadian CBD deal, done. The third was the 1600 store pharma chain, soon we will have this too. Need to seriously ramp up the production, and the price will be half the price it is now.
Dr. Chris Otiko interview with Brewer Media explaining VitaStem
Good Morning VDRM! I'll bet everyone is looking forward to a beautiful long weekend, I know I am.
As for the email I sent out last Monday, no reply yet. I'll be resending it later today and I will add the additional questions to it that were submitted late.
I think we as long share holders know what we own here. Don't let the noise distract you from the Big picture here with ViaDerma. Hang in there and hold on tight, the rise has just begun.
It would be nice to close into the green for the weekend and don't forget to spread the good news about VDRM to all your friends this holiday weekend.
Nice catch!
VIADERMA INC. AND SUBSIDIARY CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2018 (UNAUDITED) https://backend.otcmarkets.com/otcapi/company/financial-report/193710/content
Yes, I did. I believe that means they are now in full compliance of SEC regulations.
That's funny, my first buy of VDRM was $.0046 and 3 weeks later I bought a ship-load at $.0009 just a month before it ran up to a high of $.07+ and then came the Keough debacle.
Today is just more trading on the low end of the trading channel (.0075-.0085} over the past few weeks.
Just buy on the dips.
Good luck with that!
I think they are all too busy shipping VitaStem around the world to be answering silly questions.
Keeping the faith!
Nothing yet...
That's the excellent sign of a "Bull-Run".
To quote the President. "All publicity is good for the company, good or bad, it get the name out there".
I emailed Viaderma the questions @ 12:15PM CST. I'll report back when I receive a reply.
Show your proof that Viaderma has a pending suit, and not some other company. Your post continue to be misleading.
Post what proof you have.
I won't argue with the share count, but there are No Pending lawsuits.
Maybe you should look elsewhere for a company that will meet your investment needs if this one doesn't suit you.
Questions for VDRM management...
1. When will we see the 500 units sold per month reflected in the financials?
2. Is the company actively pursuing the diabetic ulcer market and how are they marketing this field?
3. Is the management still expecting to market in Japan (through Galaxy) and the Philippian markets?
4. Will there be an increase in advertising to get the word out there now that production of Vitastem has ramped-up production?
5. I believe the share price is under valued at these levels and in consideration to the outstanding share count, in your opinion, what PPS value would you put on VDRM at this time?
Send me or post your questions for management!
You're spot on with that post. I've also mentioned in past post that they need to concentrate the funds and time on the primary product. Spreading themselves and our shares all over the place is a difficult way to execute a start-up business. I learned the same lesson when I started a business, it's an armature business plan. I hope he has learned from the experience before the money dries up.
Smarty, Thanks for your comment, but I respectfully disagree that the photos have been altered. After reading your post, I carefully examined the photos (The ones on the I-hub intro, which I believe are the same as on the ViaDerma site) and I can honestly say I do not see evidence of them being altered. As for the product reviews, I myself, my son and my skeptical wife (RN) have all experienced excellent wound healing results using VitaStem along with many of the members on this board.
When I email the management, I will ask them for an update concerning the diabetic wound market. The diabetic market is what initially drawn me to buying VDRM, a large market where it will make a huge life changing impact.
Thanks for your post
Good morning VDRM,
Now that we have all digested the most recent company financial filings, does anyone have any questions to ask the company? I will be sending the an email soon asking them to explain the 500 units sold per month and when will we see it reflected in the financials.
WTF are you talking about? What disinformation do you claim I stated?
The intent to tear down this company is somewhat overwhelming, but they just keep expressing their speculation and not the facts. The fact is... VDRM is bringing new products to market and they can't stop the train.
No confusion here, until they do file, the status is dismissed. I'm not going to speculate what Keough plans are like some on this board.
Well, whomever is paying the guy for what he does, they’re getting their money’s worth. I just don’t care for the side of the trade he’s on.
Good question, but I don’t claim to be an expert on Keogh or his businesses, but I’m sure there are a few here that could answer your question.
I do know why Viaderma has been invited; they have an outstanding product that repairs skin ranking far above the others.
Why is "Dismissed" so confusing to some?
February 06, 2018 08:00 ET
The Lawsuit against ViaDerma, Inc. has been Dismissed in US District Federal Court as the Company Vigorously Defends its Patents, Product Line and its Shareholders
The Company has been successful as the Lawsuit filed by Steven Keough or OPD HOLDINGS, LLC, and KASTEN, INC., Plaintiffs, in South Dakota has been Dismissed without Prejudice; The Company continues to evaluate its own claims against the Plaintiffs & Keough
LOS ANGELES, CA--(Marketwired - February 06, 2018) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company's legal counsel, Austin Legal Group, has been successful in having the complaint filed by Steven J. Keough in a South Dakota Federal Court, dismissed without prejudice. The complaint alleged certain technical issues dating back to 2011, which the Company believes have been addressed and the Judge dismissed the case. The Company has filed provisional patents on several products, and their pending status has already gone through a screening process by the USPTO.
The Company's President, Dr. Christopher Otiko, stated, "the Company's legal counsel has vigorously defended this civil legal action to protect our shareholders and the Company's patent pending product line. The Company will continue to aggressively defend any legal action that will affect the progress ViaDerma, Inc. has made through its innovation, hard work and sacrifice. The Company continues to move ahead with its aggressive sales growth goals and new product development plans for 2018 and beyond!"
.First of all, let's first see how the Theney case turns out. I read the case files and I'm convinced that case is a frivolous as the Keough case and we all know how that ended, dismissed. Besides, that case is a different company and other than the Otiko connection, whatever the outcome of that case VDRM has zero liability concerning it. Secondly, BiogenX is 25% owned by Otiko, this has been common knowledge from the creation of the company. VDRM as a licensing agreement with BiogenX, nothing illegal there.
LOS ANGELES, May 15, 2018 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink:VDRM), is pleased to announce their participation in the upcoming Beauty & Wellness Executive Service Program, hosted by the United States Department of Commerce. ViaDerma President & CEO, Dr. Christopher Otiko will travel to Mumbai, India to attend this groundbreaking event taking place from May 30 – June 2, 2018.
This program, hosted by the U.S. Department of Commerce, in partnership with Indian distributors and manufacturers alike have provided an opportunity for U.S. business executives to visit India to obtain a comprehensive overview of the Indian beauty & wellness market and have a series of customized one-on-one meetings with importers, distributors, and partners interested in developing business with U.S. suppliers. This business-oriented program will feature stops in Mumbai and New Delhi. Responsible for organizing this trip on behalf of ViaDerma is The Brewer Group. Led by Ambassador Jack Brewer, The Brewer Group has recently expanded its efforts to manage the ongoing growth and development of ViaDerma; at a time when ViaDerma is seeing unmeasured growth.
With over 1.3 billion people, India holds the world’s second largest population. According to the Indian Acne Market Report for 2016-2025, the Indian dermatology market grew from $608MM USD in 2012 to $1.1 Billion USD in 2016, with five years compound average growth rate of 12.59 percent. The acne market has grown from $48MM USD in 2012 to $78.5MM USD in 2016. As part of ViaDerma’s GLOBAL EXPANSION, now is the time for such an innovative product like Vitastem to be introduced to the Indian market. ViaDerma is excited to be welcomed to India by acclaimed Bollywood Actress, producer and theater artist Neetu Chandra.
“This is a magnificent opportunity for ViaDerma to meet with and show Indian healthcare companies our cutting edge product that has proven to change the lives. ViaDerma is extremely excited to introduce Vitastem to India and its many healthcare providers.” Dr. Christopher A. Otiko – President / CEO, ViaDerma
That's generally solid advice for any Penny-Stock investments.
The A/R hasn't changed, that's the problem. I was expecting 1500 units sold and at least reported in the first quarter A/R. The only thing I can think of why they didn't report is because they sell VitaStem though BiogenX and there maybe a one quarter delay in reporting. The reason CEO Otiko stated why the fins are late, was because they where waiting on a third party. Maybe they reported without the third party info. The third party being BiogenX.
I can only assume what happened, but it's the best I can justify.
The next quarter should then post the 1500 units of VitaStem Sales and the $150K deposit(50%) from the $250,000 initial sales agreement with Vage Nigeria Ltd.
Lots of upside.
I'm a bit surprised that the VitaStem sales didn't show up in the accounts receivable. CEO needs to clarify his statements in a PR on April 02, 2018..." Vitastem is presently being sold over the internet on Amazon and on Vitastem.net. Vitastem.net sales have averaged about 500 units per month without advertising to this point. The Company is preparing for increased production to meet product demands before launching an official marketing campaign."
Not the numbers I was expecting, however I'm still keeping the faith.